Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor β1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine
✍ Scribed by B. H. A. von Rahden; B. L. D. M. Brücher; C. Langner; J. R. Siewert; H. J. Stein; M. Sarbia
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 158 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0007-1323
- DOI
- 10.1002/bjs.5426
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
Primary adenocarcinomas of the small intestine are rare. The prostaglandin biosynthetic pathway plays a major role in carcinogenesis and is linked with angiogenesis in various tumours. Promotion of tumour growth by transforming growth factor (TGF) β may be mediated through the prostaglandin pathway.
Methods
Expression of cyclo-oxygenase (COX) 1 and 2, prostaglandin E synthase (PGES), TGF-β1 and vascular endothelial growth factor (VEGF) A and C genes was analysed in 54 primary adenocarcinomas of the small intestine and corresponding normal intestinal mucosa. All patients had undergone surgical resection without previous antineoplastic therapy. Target gene expression was analysed at the mRNA level by reverse transcriptase–polymerase chain reaction and correlated with clinicopathological parameters as well as survival. COX-2 protein expression was examined by immunohistochemistry.
Results
Expression of COX-2 protein was detected immunohistochemically in 98 per cent of the carcinomas. COX-1, COX-2, VEGF-A, VEGF-C, PGES and TGF-β1 mRNA expression varied markedly in different tumours, but all were overexpressed compared with levels in normal intestinal mucosa. There were significant associations between levels of COX-1, COX-2, TGF-β1 and PGES mRNAs and those of VEGF-A and VEGF-C.
Conclusion
Correlations between levels of mRNA for COX-1, COX-2, TGF-β1 and PGES and those for proangiogenic factors VEGF-A and VEGF-C suggest a role for these factors in the propagation of primary adenocarcinomas of the small intestine.